- Home
- BCG vs BLRX Comparison
BCG vs BLRX Comparison
Compare BCG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | BLRX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 12.0M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BCG | BLRX |
|---|---|---|
| Price | $1.15 | $2.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 23.9K | 15.2K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.31 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $1.10 | $2.15 |
| 52 Week High | $3.44 | $4.56 |
Technical Indicators
Market Signals| Indicator | BCG | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 40.74 |
| Support Level | N/A | $2.18 |
| Resistance Level | $1.65 | $2.51 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 17.31 | 14.81 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.